EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment

Yuzi Cao, Indah Widyahening, Xiaodong Sun iD, Sheyu Li iD

Diabetes, Obesity and Metabolism · 2025-11 · 27 (S10) · 3-14

DOI: 10.1111/dom.70060 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 26.08.2025. Verfasst von Yuzi Cao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, MAGIC China Centre, Cochrane China Centre, Chinese Eviden…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, 1.3.5 Projects for Disciplines of Excellence Clinical Research Incubation West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of type 2 diabetes has been rising in China, India and Southeast Asia for decades, challenging their healthcare systems. With region‐specific determinants such as genetics, lifestyle transition and early‐life environment, people with type 2 diabetes showed their unique phenotypes, including being, on average, younger in age, with lower BMI but higher percentage body fat mass, higher postprandial glucose and poorer beta‐cell function at onset. These features invalidated the implementation of some trial evidence from the Caucasian population when informing guideline recommendations and clinical decision‐making. For example, α‐glucosidase inhibitors and DPP4 inhibitors, targeting postprandial glucose, showed greater effectiveness and acceptability in Chinese people with type 2 diabetes. The indispensable use of insulin in people with severely impaired beta‐cell function is common in China, India and Southeast Asian countries but induces the accumulation of body fat mass, which further worsens the prognosis of the people. GLP‐1 receptor agonists show strong weight‐lowering effects and cardiovascular protection and provide additional benefits for Asian people compared to Caucasians with the same levels of BMI. Adding GLP‐1 receptor agonists to people receiving insulin may neutralise the adverse effect of body weight gain. Clinicians and patients should consider the unique features of the population before making decisions, and policymakers should be aware of the pragmatic determinants during the implementation of the overseas evidence. The adoption of international trials to the region by adjusting their distinct features may improve the relevance of evidence and the treatment response at the individual level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsHumansAsia, SoutheasternChinaDipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsIndiaInsulinSoutheast Asian PeopleEast Asian People

Stichwörter der Autor:innen

diabetes complicationsinsulin resistanceinsulin secretiontype 2 diabetes

Substanzen

Dipeptidyl-Peptidase IV InhibitorsGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, MAGIC China Centre, Cochrane China Centre, Chinese Evidence-based Medicine Centre, West China Hospital of Sichuan University, C…
  • Department of Community Medicine, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
  • Department of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang, China.

ORCID-Profile: Xiaodong Sun, Sheyu Li

Förderung

  • National Natural Science Foundation of China
  • 1.3.5 Projects for Disciplines of Excellence Clinical Research Incubation West China Hospital, Sichuan University

Zitieren

APA

Cao, Y., Widyahening, I., Sun, X., & Li, S. (2025). Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment. Diabetes, Obesity and Metabolism, 27(S10), 3-14. https://doi.org/10.1111/dom.70060

Vancouver

Cao Y, Widyahening I, Sun X, Li S. Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment. Diabetes, Obesity and Metabolism. 2025;27(S10):3-14. doi:10.1111/dom.70060

BibTeX
@article{Cao2025,
  author = {Cao, Yuzi and Widyahening, Indah and Sun, Xiaodong and Li, Sheyu},
  title = {Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {S10},
  pages = {3--14},
  doi = {10.1111/dom.70060}
}
Kostenlos starten →